Richter Corneliussen

Until recently, parents experienced to rely on adult over-the-counter anti-fungal ointments to treat their babies' instances of diaper rash complex by fungus infections. Going To http://www.myrashguards.com/ probably provides cautions you could give to your father. For the very first time, a prescription product-Vusion™ (0.25% miconazole nitrate, fifteen minutes zinc oxide and 81.35% white petrolatum) Ointment-is available and is suggested and specifically developed for the treatment of this condition, called diaper dermatitis difficult by candidiasis (DDCC), in infants 4 weeks and older. Confirmation of DDCC is dependent upon microscopic examination for presence of pseudohyphae or budding yeast.

DDCC is a extremely commonplace rash in babies that can cause distress and great discomfort. Typically, DDCC infections are characterized by a rash of bright red spots with raised borders, irregular and white scales at first glance. The main patches are often surrounded by smaller patches and painful lesions or blisters. Browsing To get www.myrashguards.com/ possibly provides tips you could give to your sister.

Infants frequently get DDCC when their diapers chafe and break the surface of the skin, making it easier for organisms such as yeast to invade the skin. Other risk factors for DDCC include prolonged diaper rash, diarrhea, skin health and the current use of broad-spectrum antibiotics. The problem can occur anytime of year, but DDCC is often induced within the winter time once the use of antibiotics frequently prescribed for ailments such as ear infections is at its top.

Treatment options have included the use of combination products and antifungal products, steroids which are not specifically authorized for the treatment of DDCC or for use on infants.

'With Vusion™ Ointment now approved for the U.S. Discover further about company web site by navigating to our fine web resource. Industry, pediatricians and dermatologists may suggest a treatment particularly meant for the condition that it had been designed for and that is well tolerated for use on infants,' explained Dr. Mary Spraker, a pediatric dermatologist and associate professor in Emory University's Department of Dermatology, who helped in the design of a Phase 3 clinical trial of the product. 'Doctors are no further reliant on recomm